Piper Jaffray Companies restated their overweight rating on shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) in a research note published on Thursday, November 2nd, The Fly reports. They currently have a $5.00 price objective on the biotechnology company’s stock.
A number of other research firms also recently commented on GNCA. Zacks Investment Research downgraded shares of Genocea Biosciences from a buy rating to a hold rating in a research report on Monday, July 17th. Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $12.00 target price on the stock in a research report on Monday, July 24th. ValuEngine raised shares of Genocea Biosciences from a sell rating to a hold rating in a research report on Monday, July 24th. Cowen and Company restated an outperform rating and issued a $40.00 price target on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Stifel Nicolaus cut shares of Genocea Biosciences from a buy rating to a hold rating and lowered their target price for the stock from $15.00 to $2.50 in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $6.06.
Shares of Genocea Biosciences (GNCA) opened at $1.16 on Thursday. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. Genocea Biosciences has a twelve month low of $1.03 and a twelve month high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08). During the same period in the previous year, the company posted ($0.45) EPS. equities analysts expect that Genocea Biosciences will post -1.91 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new position in shares of Genocea Biosciences during the 2nd quarter valued at about $100,000. Ameriprise Financial Inc. boosted its position in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in Genocea Biosciences in the second quarter valued at about $125,000. Rhumbline Advisers acquired a new position in Genocea Biosciences in the second quarter valued at about $157,000. Finally, New York State Common Retirement Fund acquired a new position in Genocea Biosciences in the second quarter valued at about $159,000. 34.05% of the stock is currently owned by institutional investors.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with our FREE daily email newsletter.